Bis- (3- (3,5-di-tert-butyl-4-hydroxyphenyl) propyl) selenide, having antioxidant and hypoglycemic activity

FIELD: chemistry.

SUBSTANCE: invention relates to selenium-containing phenol compound - bis-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl)selenide with formula: .

EFFECT: disclosed compound exhibits high antioxidant activity, low toxicity and hypoglycaemic action with underlying diabetes, and can be used in medicine, veterinary and experimental biology.

1 cl, 1 dwg, 3 tbl, 5 ex



Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to biotechnology. Claimed is a method of enriching probiotic microorganisms, selected from yeasts and bacteria, with organic selenium. A microorganism is cultivated in a medium, containing a compound of general formula or its salt, a stereoisomer or a mixture of stereoisomers in any ratio or its ether derivative. Also claimed are probiotic bacteria, enriched with organic selenium, with the content of organic selenium more than 50 mcgSe/g by dry weight, with the content of selenomethionine constituting more than 50% of the total content of selenium in the bacterium. Also claimed is application of enriched by the said way probiotic bacteria in a cosmetic, pharmaceutical or food product.

EFFECT: invention provides enrichment of probiotic microorganisms with non-toxic organic selenium with an increased output.

12 cl, 6 dwg, 4 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of enriching a photosynthesising microorganism, selected from green algae and blue-green algae with organic selenium. The photosynthesising microorganism is cultured in a medium containing a compound of the type of selenium-containing hydroxy acid of general formula , with a salt, ester or amide derivative of said acid. Content of organic selenium in the green algae or blue-green algae is higher than 1000 mcgSe/g of dry weight. Also disclosed is use of the enriched microorganisms as a cosmetic, pharmaceutical or food agent.

EFFECT: enriching photosynthesising microorganisms with non-toxic organic selenium with high output.

16 cl, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to application of effective quantity of selenate or its pharmaceutically acceptable salt in methods and compositions for treatment or prevention of neurological disorders, which are are not related to tauopathy. Neurological disorder, which is not related to tauopathy, is not a-synucleinopathy. Effective quantity of selenate or its pharmaceutically acceptable salt delivers over-dietary quantity of selenium. In some implementations invention relates to application of selenate or its pharmaceutically acceptable salt in combination with other means of therapy for application in methods of treatment or prevention of neurological disorders, which are not related to tauopathy.

EFFECT: treatment or prevention of neurological disorders, which are not related to tauopathy.

2 ex, 9 dwg

FIELD: chemistry.

SUBSTANCE: method comprises the following steps: reaction of 3-methylselenopropion aldehyde of formula (I): with an alkali metal cyanide of formula M+CN-, preferably in the presence of an alkali metal bisulphite salt of formula M+HSO3-, where M denotes an alkali metal atom, in a polar protic solvent, to obtain 2-hydroxy-4-methylselenobutyronitrile of formula (II): , hydrolysis of the compound of formula (II) in the medium of hot concentrated sulphuric acid, in a polar protic solvent, to obtain the desirable compound of formula (IV): , or hydrolysis of the compound of formula (II) in the medium of hot concentrated sulphuric acid, in a polar protic solvent, to obtain a compound of formula (III): , which can be hydrolysed in the medium of hot concentrated strong acid to obtain a compound of formula (IV). The compound of formula (IV) can be converted to one of its salts after adding a physiologically acceptable base. The invention also discloses a method of preparing a mixture of 2-hydroxy-4-methylselenobutyric acid and 2-hydroxy-4-methylthiobutyric acid and use thereof, 2-hydroxy-4-methylselenobutyronitrile and use thereof, and a dietary composition.

EFFECT: invention simplifies production of 2-hydroxy-4-methylselenobutyric acid.

17 cl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to N,Se-substotuted of N'-1-(alkyl(hetero)aryl)-N'-1-(alkyl(hetero)aryl)isoselenourea: , where R1 represents alkyl, cycloalkyl, alkenyl, aryl; R2 - hydrogen or lower alkyl; R3, R4 can be similar or different and independently represent aryl, heteroaryl; R5 represents hydrogen or lower alkyl; m=0-2, n=1-3; X represents anion residue of inorganic or organic acid, symbol "*" means possibility of presence of chiral carbon atom.

EFFECT: obtaining N,Se-substotuted of N'-1-(alkyl(hetero)aryl)-N'-1-(alkyl(hetero)aryl)isoselenourea, possessing neuroprotective action.

8 ex

FIELD: medicine.

SUBSTANCE: invention refers to a new product in the form of solution for treatment of benign, virus, premalignant and malignant nonmetastasing skin affections, dysontogenetic lesions of visible mucous membranes, skin mycoses, wrinkle correction and senile pigment spots. The product represents a compound of general formula H2SeO3·x·[R-CXY-(CH2)m-COOH], where x=2-6 prepared from reaction of selenium dioxide and haloid carboxylic acids of general formula R-CXY-(CH2)m-COOH, where R = phenyl, alkyl of general formula CnH2n+1; n=1-5, X=H or Y, Y=F, CI, Br or J, m = 0-10. Besides, the invention concerns a product in the form of solution for treatment benign, virus, premalignant and malignant nonmetastasing skin affections, dysontogenetic lesions of visible mucous membranes, skin mycoses, wrinkle correction and senile pigment spots, containing 0.1-50 wt % of said product, 1-99 wt % of haloid carboxylic acids and the rest - water. Also the invention concerns method of treatment of various skin diseases, including topic applications of the product.

EFFECT: improved clinical effectiveness of the product and method of treatment.

6 cl, 3 dwg, 1 tbl, 68 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of butyric acid of the formula (I): wherein A means carboxyl or (C6-C18)-alkoxycarbonyl; B means ethylene group -CH2-CH2-; R1 means benzyl optionally substituted in phenyl ring, optionally substituted phenyl or optionally substituted pyridyl; Z represents sulfur (S) or selenium (Se) atom; n means a whole number = 0, 1 or 2; R2 represents radical chosen from optionally substituted phenyl, optionally substituted benzopyridine, optionally substituted benzothiazole, optionally substituted quinolyl, optionally substituted naphthyl, optionally substituted triazole and radical of the formula: Also, invention describes methods for synthesis of compounds of the formula (I) and pharmaceutical composition based on thereof. Compound can be used in preparing a medicine designated for treatment or prophylaxis of dyslipidemia and diabetes mellitus.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

9 cl, 1 tbl, 81 ex

The invention relates to medicine and applies to new analogues of fatty acids of General formula (1), pharmaceutical compositions for and methods of treating or preventing obesity, hypertension, fatty infiltration of the liver, multiple metabolic syndrome nutritional compositions and method of improving the quality of such products as meat, milk and eggs

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.

EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.

4 dwg, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.

EFFECT: novel compound, possessing useful biological properties, has been obtained.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.

EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.

4 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.

EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: medicine.

SUBSTANCE: integrated resort treatment is conducted. A patient takes carbonic sodium chloride mineral water. The mineral water is heated to a temperature of 37°C before use and taken at 3 ml per 1 kg of body weight 3 times a day 40 minutes before meals. The therapeutic course makes 18 days. The patient also takes "dry" carbon dioxide baths with the CO2 concentration of 1.2-1.4 g/l at the water temperature of 35°C. The water temperature is reduced to 32°C by the end of the course. The procedure length is 15-20 minutes. CO2 is supplied from a balloon into a special box compartment at a rate of 15-20 l/min. The gas mix temperature ranges from 28°C to 38°C. The procedures are performed every second day. The course of 8-10 procedures is required.

EFFECT: method provides normalising the complete blood count, blood sugar, common urine analysis, improving the visual analysis health, renal blood flow, ophthalmic parameters by the integrated intake of mineral water and dry carbon dioxide baths, optimum regimen and length of the therapeutic course.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to novel analogues of a glucagon-like peptide, and can be used in medicine to activate insulin expression in mammals and to treat sugar diabetes.

EFFECT: obtained peptide derivatives have a peptide imitating linker and provide prolonged action when treating diabetes and other diseases associated with insulinotropic peptides, gastrointestinal functions and glucagon levels.

25 cl, 23 ex